Background/Aim: Mammalian target of rapamycin (mTOR) plays an important role in papillary thyroid carcinoma (PTC) cell progression. CZ415 is a novel, highly-efficient and specific mTOR kinase inhibitor. The current study tested the potential anti-tumor activity of CZ415 in human PTC cells. Methods: The established (TPC-1 cell line) and primary human PTC cells were treated with CZ415. Cell survival and growth were tested by Cell Counting Kit-8 assay and BrdU ELISA assay, respectively. Cell apoptosis was tested by caspase-3/-9 activity assay, Hoechst-33342 staining assay and single-stranded DNA ELISA assay. Cell cycle progression was tested by propidium iodide-FACS assay. The mTOR signaling was tested by Western blotting assay and co-immunoprecipitation assay. The mouse xenograft tumor model was applied to study the effect of CZ415 in vivo. Results: In cultured human PTC cells, treatment with CZ415 at nM concentrations significantly inhibited cell survival and growth. CZ415 induced apoptosis activation and cell cycle arrest in human PTC cells. CZ415 disrupted assembling of mTORC1 (mTOR-Raptor association) and mTORC2 (mTOR-Rictor-GβL association) in TPC-1 cells, which led to de-phosphorylation of the mTORC1 substrates (S6K1 and 4E-BP1) and the mTORC2 substrate AKT . Further studies show that the autophagy inhibitor 3-methyladenine (3-MA) or Beclin-1 shRNA aggravated CZ415-induced cytotoxicity against PTC cells. In vivo, CZ415 oral administration inhibited TPC-1 xenograft tumor growth in mice. Conclusion: Our results show that mTOR blockage by CZ415 inhibits PTC cell growth in vitro and in vivo.
Introduction
Thyroid cancer is a main health threat in China [1, 2] and around the world [3, 4] . Its incidence has been tripled in the past decades [3] [4] [5] . Over three-quarter of thyroid cancers are papillary thyroid carcinomas (PTC) [1, 2] . PTC's pathogenesis is still not fully understood [1, 2] . Existing studies suggest that radiation and genetic susceptibility contribute to the
Apoptosis assay
Following the treatment, cells were stained with nuclei dye Hoechst-33342 (Sigma). Normal nuclei show faint delicate chromatin staining, nuclei showing intensified Hoechst-33342 condensation/brightness (early apoptotic cells) or fragmentation (late apoptotic cells) were labeled as apoptotic cells.
ssDNA ELISA assay
The production of denatured single-stranded DNA (ssDNA) is an established marker of cell apoptosis, which was examined by a nucleosomal monoclonal antibody using the ELISA format as described previously [24] . The ssDNA ELISA OD value at 450 nm was tested.
Western blotting assay
The quantified lysate proteins (40 μg per treatment of each lane) were separated by 10-12% of SDS-PAGE gels, and were electrophoretically transferred to the PVDF membrane (Millipore, Shanghai, China). The blot was blocked (in 10% milk), followed by probing with applied primary and secondary antibodies. Enhanced chemiluminescence (ECL) reagents were used to analyze targeted protein expression, and β-Tubulin ("Tubulin") was always tested as the protein loading control. mTOR co-Immunoprecipitation (Co-IP) The protein lysates (1000 μg per treatment) were pre-cleared. The pre-cleared lysate samples were incubated with anti-mTOR antibody (Cell Signaling Tech) overnight. Protein G Sepharose (30 µL per treatment, Sigma) was then added again to the lysates. mTOR complexes were then washed and subjected to Western blotting assay.
shRNA The lentiviral particles with Beclin-1 shRNA (sc-29797-V), Rictor shRNA (sc-61478-V) as well as the scramble control shRNA were purchased from Santa Cruz Biotech (Shanghai, China). The shRNA-containing lentivirus was added to cultured TPC-1 cells for 12 hours. After infection, puromycin (3.0 μg/mL) was added to select stable cells if necessary. Knockdown of targeted protein (Beclin-1 or Rictor) was confirmed by the Western blotting assay.
In vivo tumorigenesis assay
The female severe combined immunodeficient (SCID) mice (4-5 weeks of age, 17.0-18.0g of weight) were purchased from the Experimental Animal Center of Suzhou University (Suzhou, China). TPC-1 cells (5×10 6 cells of each mouse) were injected to the dorsal flank of the SCID mice. Within three weeks, the volume of each tumor was around 100 mm 3 , and the tumor-bearing mice were randomly assigned into two groups (10 mice per group), receiving CZ415 or the vehicle control. Tumor size was measured every 6 days. The tumor volume = (D×d 2 )/2 was applied to evaluate tumor volume, where "D" is the longest diameter and "d" is the shortest diameter. All experiments on animal were performed according to the Animal Experimental Ethics Committee of authors' institution.
Statistics
The results were expressed as the mean ± standard deviation (SD). Statistical significance (p < 0.05) was evaluated by one-way ANOVA followed by Bonferroni post hoc test (SPSS 18.0, Chicago, IL). 
Results

CZ415 inhibits human papillary thyroid carcinoma cell survival and growth
The structure and molecular weight of CZ415 were presented in Fig. 1A . TPC-1 is an established human PTC cell line [25, 26] . TPC-1 cells were cultured in FBS-containing complete medium, and were treated with different concentrations (10-1000 nM) of CZ415. The cell growth curve results in Fig. 1B show that treatment with CZ415 at 100/1000 nM significantly inhibited TPC-1 cell growth. The anti-growth activity of CZ415 was dosedependent, and 10 nM of CZ415 was ineffective (Fig. 1B) . CZ415 (100/1000 nM) also inhibited BrdU incorporation in TPC-1 cells (Fig. 1C) . Cell Counting Kit-8 (CCK-8) assay was applied to test TPC-1 cell viability. The results demonstrate that CZ415 dose-dependently decreased TPC-1 cell CCK-8 viability optic density ("OD", Fig. 1D ). The clonogenicity assay results show that the number of viable TPC-1 colonies was significantly decreased following 100/1000 nM of CZ415 treatment (Fig. 1E) .
Then we tested the potential effect of the novel mTOR kinase inhibitor [20] [21] [22] on the primary human PTC cells. Four lines of primary human PTC cells were established, and named as "Line1/2/3/4". Line1 and Line2 primary human PTC cells were PTEN deficient with high basal AKT activation (Fig. 1F ). Line3 and Line4 cells were PTEN positive with weak AKT activation (Fig. 1F) . Treatment with CZ415 (1000 nM) inhibited viability (CCK-8 OD) of all four lines of primary human PTC cells (Fig. 1G) . PTEN-depleted cells (Line1 and Line2) were more sensitive to CZ415 (Fig. 1G) .
In order to test the activity of CZ415 in the non-cancerous cells, two lines of primary human thyroid epithelial cells were cultured, named as "Epi-1" and "Epi-2" (See Methods). Notably, treatment with CZ415 at a high concentration (1000 nM) failed to inhibit the viability of these epithelial cells (Fig. 1H ). These results demonstrate an unique response of this mTOR kinase inhibitor against cancerous cells.
CZ415 induces apoptosis activation in human papillary thyroid carcinoma cells
Apoptosis activation can be a main reason of growth inhibition and cytotoxicity in cancer cells [27, 28] . Western blotting assay results in Fig. 2A show that CZ415 (100/1000 nM) treatment induced cleavage of both caspase-3 and caspase-9 in TPC-1 cells. The activity of caspase-3 and caspase-9 were increased significantly in CZ415 (100/1000 nM)-treated cells (Fig. 2B) . Cleaved-caspase-3 and cleaved-caspase-9 will travel into cell nuclei, causing DNA cleavage. The results show that the content of single strand DNA ("ssDNA") was increased after CZ415 (100/1000 nM) treatment (Fig. 2C) . Hoechst-33342 staining assay was also performed to test cell apoptosis. The non-apoptotic normal nuclei showed faint delicate (Fig. 2D ). These results suggest that CZ415 induced apoptosis activation in TPC-1 cells. Hoechst-33342 apoptotic nuclei staining assay results in Fig. 2E show that CZ415 (1000 nM, 48 hours) induced apoptosis activation of all four lines of primary human PTC cells. Its pro-apoptotic activity is more significant in two lines of PTEN-depleted human PTC cells ("Line1/2") ( Fig. 2E) . Conversely, CZ415 failed to induce significant apoptosis in primary thyroid epithelial cells (Fig. 2F) .
CZ415 disrupts PTC cell cycle progression
We also analyzed cell cycle distribution in CZ415-treated PTC cells. Quantified results in Fig. 3A confirmed that treatment with CZ415 (1000 nM, 24 hours) disrupted TPC-1 cell cycle progression. Following the CZ415 treatment, G0-1 phase TPC-1 cells were increased, and the G2-M phase cells were decreased (Fig. 3A) . These results suggest that CZ415 induced G1-S arrest in TPC-1 cells. It has been previously shown that mTOR is required for the expression of several cell cycle-related proteins, including Cyclin D1 [29] and Cyclin E1 [30] . Here, our results show that Cyclin D1 and Cyclin E1 were downregulated by CZ415 (1000 nM, 12 hours) in TPC-1 cells (Fig. 3B-C) .
CZ415 blocks mTORC1 and mTORC2 activation in PTC cells
mTOR is in two multiple protein complexes (mTORC1/2). The mTOR-Raptor complex ("mTORC1") can phosphorylate S6K1 and 4E-BP1. mTOR-Rictor-GβL complex ("mTORC2") phosphorylates AKT at Ser-473 [14] . The co-immunoprecipitation ("Co-IP") assay was performed to test the assembly of these two mTOR complexes. Results in Fig. 4A show that the mTOR-Raptor complex and mTOR-Rictor-GβL complex were disrupted by CZ415 (1000 nM, 2 hours) in TPC-1 cells. Expression of mTOR complex proteins, including mTOR, Raptor, Rictor and GβL, were unchanged after CZ415 treatment (Fig. 4A, "INPUT") . Treatment with Fig. 3 . CZ415 disrupts PTC cell cycle progression. TPC-1 cells were treated with CZ415 (1000 nM), cells were cultured in the conditional medium for applied time, cell cycle distribution was analyzed by PI FACS assay (A); Expression of listed proteins were shown (B), and results were quantified (C). Data were presented as mean ± standard deviation (SD, n=5). *p<0.05 vs. "C" group. 
CZ415 almost completely blocked phosphorylation of mTORC1 substrates S6K1 (Thr-389) and 4E-BP1 (Ser-65), as well as the mTORC2 substrate AKT (Ser-473) (Fig. 4B) . Total S6K1, 4E-BP1 and AKT1 were unchanged (Fig. 4B) . Furthermore, the activation or phosphorylation of ERK1/2 was also not affected by CZ415 (Fig. 4B) . Western blotting assay results in Fig. 4C show that CZ415 treatment blocked phosphorylation of S6K1 (Thr-389) and AKT (Ser-473) in the primary human PTC cells ("Line-1"). Ad- I) or the primary PTC cells ("Line1", F and J) were treated with CZ415 (1000 nM), P242 (1000 nM), MK-2206 (1000 nM), RAD001 (1000 nM), or infected with Rictor shRNA ("shRictor") lentivirus; Cells were further cultured for 72 hours, and cell viability was tested by CCK-8 assay (E, F, I and J). Rictor expression was also shown (E and F, the upper panel). Data were presented as mean ± standard deviation (SD, n=5). *p<0.05 vs. "C" group. # p<0.05 vs. "CZ415" only group. The experiments were repeated three times, and similar results were obtained. (Fig. 4D) . This might explain why the epithelial cells were not killed by the mTOR kinase inhibitor ( Fig. 1 and 2 ). ERK1/2 phosphorylation and expression were unchanged after CZ415 treatment ( Fig. 4C and D) . These results demonstrate that CZ415 blocked mTORC1 and mTORC2 activation in human PTC cells.
We compared CZ415 activity with other known AKT-mTOR inhibitors, including the AKT specific inhibitor MK-2206 [31] [32] [33] and the mTORC1 inhibitor RAD001 [34, 35] . Results in Fig. 4E show that CZ415 was more potent than MK-2206 and RAD001 in inhibiting TPC-1 cell survival. Meanwhile, CZ415-induced cytotoxicity was more significant than mTORC2 inhibition by Rictor shRNA (Fig. 4E) . The similar results were also observed in the primary human PTC cells ("Line-1"), and CZ415's cytotoxicity was more robust than MK-2206, RAD001 and Rictor shRNA (Fig. 4F) . Thus, mTORC1/2 dual inhibition by CZ415 is more efficient in killing PTC cells than blockage of either mTORC1 or mTORC2.
Importantly, treatment with PP242, another known mTOR kinase inhibitor [36] , had no significant effect on the assembling of mTORC1 and mTORC2 in TPC-1 cells (Fig. 4G) . The expression of mTOR complex proteins, mTOR, Raptor, Rictor and GβL, were not affected by PP242 (Fig. 4G, "Input") . PP242 treatment only resulted in partial Beclin-1 expression was tested by Western blotting assay (A, the upper panel); Cell survival and apoptosis were tested by CCK-8 assay (A, the lower panel) and Hoechst-33342 staining assay (B), respectively. Data were presented as mean ± standard deviation (SD, n=5). *p<0.05 vs. "C" group.
# p<0.05 vs. "shC" group. The experiments were repeated three times, and similar results were obtained.
A.
B. ) and mice body weights (D, in gram) were recorded every 6 days for a total of 42 days; Estimated daily tumor growth (in mm 3 per day) was calculated as described (B); At day-42, each single tumor of the two groups was isolated and weighted (C). Data were presented as mean ± standard deviation (SD, n=10). At Day-3 (E) and Day-6 (F), 2 hours after initial CZ415/Vehicle treatment, one tumor per group was isolated, the tumor tissues were lysed, and expression of listed proteins in tumor lysates were tested by the Western blotting assay.*p<0.05 vs. "Vehicle" group. (Fig. 4H ). ERK1/2 activation, as expected, was not affected by PP242 (Fig. 4H) . Consequently, PP242 was less effective than CZ415 in inhibiting the viability of PTC-1 cells (Fig. 4I ) and the primary human PTC cells ("Line-1") (Fig. 4J) .
Autophagy inhibition sensitizes CZ415-induced cytotoxicity in PTC cells
It has been shown that mTOR blockage can induce feedback autophagy activation, which might serve as a pro-survival factor to inhibit cancer cell death [37] [38] [39] . To block autophagy, pharmacological and genetic stragies were utilized. Three-methyladenine (3-MA) is a well-known autophagy inhibitor [40] . Beclin-1 is a key protein of autophagy initiation and progression [41, 42] . Beclin-1 knockdown has been utilized to block autophagy in cancer cells [43] . The applied lentiviral Beclin-1 shRNA induced efficient knockdown of Beclin-1 in TPC-1 cells (Fig. 5A, the upper panel) . Significantly, CZ415 (100/1000 nM)-induced TPC-1 cell viability reduction (Fig. 5A , the lower panel) and apoptosis activation (Fig. 5B) were potentiated by 3-MA and Beclin-1 shRNA. These results imply that autophagy inhibition could increase CZ415's sensitivity, and autophagy could be a key resistance factor for CZ415 treatment in PTC cells.
CZ415 inhibits TPC-1 tumor growth in mice
At last, the potential anti-tumor activity of CZ415 in vivo was tested. TPC-1 cells were inoculated via s.c. injection to the severe combined immunodeficient (SCID) mice. When the volume of each tumor was around 100 mm 3 , tumor-bearing mice were randomly separated into two groups, which were treated with CZ415 or the vehicle control (n=10 for each group). Tumor growth curve results in Fig. 6A demonstrated that oral administration of CZ415 (20 mg/kg body weight [22] , daily for 24 days) significantly inhibited TPC-1 xenograft tumor growth in mice. The daily tumor growth was calculated using the formula: [Tumor volume at day-42 (mm Fig. 6B show that estimated daily tumor growth was 24.70 ± 3.05 mm 3 per day in the vehicle mice, and it reduced to 8.09 ± 2.01 mm 3 per day after CZ415 treatment ( Fig. 6B) . At day-42, tumors of each group were isolated and weighted, and CZ415-treated tumors weighted dramatically lower than the vehicle control tumors (Fig. 6C) . The mice body weight was not significantly different between the two groups (Fig. 6D) .
At Day-3 and Day-6, two hours after CZ415/Vehicle treatment, one tumor per group was isolated, the tumor tissues were lysed for mTOR signaling analysis. When compared to the vehicle control tumors, results show that phosphorylation of AKT, S6K1 and 4E-BP1 were largely inhibited in the tumor tissues after CZ415 treatment ( Fig. 6E and F) . These results suggest that CZ415 possibly also blocks mTORC1 and mTORC2 activation in vivo. Collectively, our results show that CZ415 could inhibit TPC-1 xenograft tumor growth in vivo.
Discussion
The traditional mTORC1 inhibitors, i.e. rapamycin and its analogs ("rapalogs"), have displayed promising anti-tumor activity [44, 45] . Whereas, the application of these inhibitors had several drawbacks [44, 45] . First, rapalogs bind to FKBP12, leading to only partial inhibition of mTORC1 [44, 45] . Second, these mTORC1 inhibitor can provoke feedback activation of multiple key oncogenic pathways, including ERK and AKT cascades [46] . Third, rapalogs have direct inhibition on mTORC2. In fact, rapamycin treatment could provoke AKT activation via the IRS-1-mediated feedback pathway [47, 48] . Fourth, the clinical administration of these mTORC1 inhibitor are usually limited due to poor solubility [44, 45] . Due to these limitations, mTOR kinase inhibitors, also known as the "second generation of mTOR inhibitors", were recently developed [44, 45] .
CZ415 is a novel, highly-efficient and specific mTOR kinase inhibitor [20] [21] [22] . It displayed an extremely superior K d (nM ranges) and applicable pharmacokinetic/pharmacodynamic Cellular Physiology and Biochemistry
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properties [22, 49] . In the current study, our results show that CZ415 disrupted the assembling of both mTORC1 (mTOR-Raptor association) and mTORC2 (mTOR-Rictor-GβL), causing de-phosphorylation of the mTORC1 substrate S6K1 and 4E-BP1 as well as the mTORC2 substrate AKT (Ser-473). CZ415 had no significant effect on ERK activation in human PTC cells. Treatment with CZ415 at nM concentrations significantly inhibited human TPC cell survival and growth, and also induced apoptosis activation and disrupted cell cycle progression. Notably, CZ415's cytotoxicity was more potent than MK-2206, RAD001 and Rictor shRNA. One interesting finding of our research was that CZ415 disrupted the assembling of both mTORC1 and mTORC2, which resulted in almost complete inhibition of mTORC1 and mTORC2 in human PTC cells. Whereas, the other known mTOR kinase inhibitor PP242 had no direct effect on mTORC1/2 assembling, and it only caused partial inhibition of mTORC1/2 in human PTC cells. Therefore, it is possible that CZ415 binding to mTOR may induce mTOR conformational change, which leads to the disassembling of both mTORC1 and mTORC2. These results can also explain the superior activity of CZ415 against human PTC cells.
In vivo, oral administration of CZ415 at a well-tolerated dose (20 mg/kg body weight) significantly suppressed TPC-1 tumor growth in mice. Importantly, CZ415 was non-cytotoxic to the non-cancerous thyroid epithelial cells, and the results of in vivo administration show that there were no apparent toxicities to the experimental mice. Therefore, the current preclinical study displayed a superior anti-tumor activity of CZ415 against human PTC cells.
Although sustained and profound autophagy could promote cell death ("autophagic cell death"), drug-induced feedback autophagy activation is mostly gentle and has pro-survival ability especially in cancer cells [28, 50, 51] . In the process of autophagy, cell degrades its own components via lysosomal machineries, which provides energy and nutrients for cell to survive [52] . mTOR is a key kinase regulating cell autophagy [53, 54] . Activation of mTOR is shown to suppress cell autophagy through directly inhibiting Ulk1, which is the upstream kinase initiating cell autophagy [55] . mTOR blockage, on the other hand, could lead to feedback autophagy activation [53, 54] . Indeed, a number of mTOR inhibitors were shown to active autophagy in cancer cells, which counteracted cell death [37] [38] [39] 56] . Conversely, autophagy inhibition can increase the sensitivity and the anti-cancer efficiency of mTOR inhibitors [37] [38] [39] . In the current study, our results show that the autophagy inhibitor 3-MA or Beclin-1 shRNA potentiated CZ415-induced cytotoxicity in PTC cells. Therefore, cell autophagy could also be a key resistance factor of CZ415 in PTC cells.
Conclusion
Together, our results demonstrate that mTOR blockage by CZ415 inhibits PTC cell growth in vitro and in vivo. CZ415 could be further studied as a promising anti-PTC agent.
